AbbVie appoints Thomas Falk (ex-Kimberly-Clark CEO) to board; Gonzalez, Tilton to retire July 1

AbbVie Inc.

Board expanded to 15; Thomas J. Falk (former Kimberly-Clark CEO) appointed as Class III director and to Audit Committee; deemed independent.
Board to shrink to 13 upon retirement of Richard A. Gonzalez and Glenn F. Tilton effective July 1, 2025.
Compensation Committee raised Robert A. Michael's 2025 annual bonus target to 165% of base salary for Chairman role.
Shareholders ratified EY as auditor and approved say-on-pay; both management and stockholder proposals to eliminate supermajority voting failed.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Richard A. Gonzalez

Director

ABBV · AbbVie Inc.

Effective: 2025-07-01
Filed: May 13, 2025, 7:59 PM ET

The Board also determined that the size of the Board will decrease from fifteen directors to thirteen directors upon the retirement of Richard A. Gonzalez and Glenn F. Tilton from the Board, effective July 1, 2025.

Departed

Glenn F. Tilton

Director

ABBV · AbbVie Inc.

Effective: 2025-07-01
Filed: May 13, 2025, 7:59 PM ET

The Board also determined that the size of the Board will decrease from fifteen directors to thirteen directors upon the retirement of Richard A. Gonzalez and Glenn F. Tilton from the Board, effective July 1, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard A. Gonzalez departed as Director at AbbVie Inc..

Action: retire
Role: Director

Exact text from the filing

The Board also determined that the size of the Board will decrease from fifteen directors to thirteen directors upon the retirement of Richard A. Gonzalez and Glenn F. Tilton from the Board, effective July 1, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Glenn F. Tilton departed as Director at AbbVie Inc..

Action: retire
Role: Director

Exact text from the filing

The Board also determined that the size of the Board will decrease from fifteen directors to thirteen directors upon the retirement of Richard A. Gonzalez and Glenn F. Tilton from the Board, effective July 1, 2025.

View on SEC.gov

AbbVie Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-047402

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.